Aligos Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.672 million. Net loss was USD 27.89 million compared to USD 21.89 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.51 a year ago.

For the full year, the company reported sales was USD 6.19 million. Net loss was USD 87.68 million compared to USD 96.05 million a year ago. Basic loss per share from continuing operations was USD 1.36 compared to USD 2.25 a year ago. Diluted loss per share from continuing operations was USD 1.36 compared to USD 2.25 a year ago.